KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, ...

Lung cancer co-opts genes that normally help a fetus develop and evade the mother’s immune system — leading to poorer ...

Zoldonrasib, an oral KRAS G12D-selective inhibitor, showed a 61% response rate and 89% disease control in previously treated ...

Erasca continues developing novel RAS-pathway cancer drugs, backed by funding through 2027 and promising early results. Find out why ERAS stock is a buy.

First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE ...

The team demonstrated that tumor cells make new fat through the KRAS-MAPK pathway. "KRAS is the master regulator of pancreatic cancer, and new medicines are now in clinical trials to bring down ...

leading to the sustained activation of the MAPK signaling pathway and ultimately driving tumorigenesis. KRAS mutations, especially G12D, G12V, and G12C, are highly prevalent in pancreatic ...

with a median target of $5.5. First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN ...